Small Molecules That Suppress IGF-Activated Prostate Cancers
Abstract
Elevated serum levels of insulin-like growth factor 1 (IGFl) have been found in prostate cancer patients, and IGFl-related signal transduction is thought to be an important factor in the development of prostate cancers. The goals of this project are to discover small organic molecules that suppress IGF-activated prostate cancers by cell-based screening and to analyze their action mechanisms. We have been taking a unique two-step approach to discovering such molecules: we first examine the phenotypic effects of chemical library members (10,000 divergent drug-like compounds) on the insulin-induced adipogensis and, by using the adipogenesis profile, we then identify organic compounds that suppress TGF- mediated growth of prostate cancer cells. Our hypothesis is that some of the compounds that block the insulin-induced adipogenesis suppress IGF-stimulated proliferation of malignant prostate cancers. In the first year of funding, we discovered, from the pool of chemicals that blocked insulin-induced adipogenesis, the drug-like compound we call 125B11 that suppress lGFI-dependent growth of prostate cancer cells but not serum-dependent growth. We are currently working on its mechanisms of action.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2004
- Accession Number
- ADA427813
Entities
People
- Motonari Uesugi
Organizations
- Baylor College of Medicine